Abstract
The sensitivity of cancer cells which exhibit multi-drug resistance phenotype to A3 adenosine receptor (A3AR) agonist N(6)-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide (IB-MECA) was studied. To establish direct relationship between P-glycoprotein (P-gp, ABCB1 and MDR1) expression and IB-MECA induced cell death, a straightforward method for precise estimation of intracellular level of this A3AR agonist was developed. We subjected three human leukaemia cell lines HL-60, K562 and K562/HHT to treatment with micromolar concentrations of IB-MECA. Although all cell lines used expressed A3AR, there was a large difference in their sensitivity to IB-MECA. While HL-60 and K562 cells were almost equally sensitive, the K562/HHT cells, which exhibit a multi-drug resistance phenotype because of overexpression of P-gp, were significantly more resistant. We found that the intracellular level of IB-MECA in K562/HHT cells was approx. 10 times lower than those in HL-60 or K562 cells. Inhibitors of P-gp, including cyclosporine A (CsA) and verapamil (Vpa), increased the intracellular level of IB-MECA and reversed the resistance of K562/HHT cells to this drug. Accordingly, shRNA-mediated down-regulation of P-gp significantly increased the intracel...Continue Reading
References
Nov 11, 1976·Biochimica Et Biophysica Acta·R L Juliano, V Ling
Sep 1, 1992·British Journal of Haematology·C LudescherJ Hofmann
Oct 15, 1989·International Journal of Cancer. Journal International Du Cancer·M H SilbermannK Nooter
Jan 1, 1989·Annual Review of Biochemistry·J A Endicott, V Ling
Dec 16, 1983·Journal of Immunological Methods·T Mosmann
Feb 27, 1996·Biochemical and Biophysical Research Communications·Y KohnoK A Jacobson
Jan 17, 1997·The Journal of Biological Chemistry·Y LavieM C Cabot
Jul 4, 1998·Trends in Pharmacological Sciences·K A Jacobson
Aug 26, 1998·FEBS Letters·M C CabotA E Giuliano
Nov 26, 1998·Japanese Journal of Pharmacology·M P Abbracchio, G Burnstock
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
Mar 8, 2000·The Journal of Cell Biology·Y Chen, S M Simon
Dec 23, 2000·Molecular Pharmacology·Z GaoJ Linden
Jan 9, 2001·Journal of Cellular Physiology·G OhanaP Fishman
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Mar 26, 2002·Biochemical Pharmacology·Seong Gon KimKenneth A Jacobson
Jun 5, 2002·Anti-cancer Drugs·Pnina FishmanIlan Cohn
Oct 1, 1957·Experimental Cell Research·H J PHILLIPS, J E TERRYBERRY
Oct 11, 2003·Pharmacology & Therapeutics·Stefania MerighiPier Andrea Borea
Dec 6, 2003·Analytical Biochemistry·Subhash D Katewa, Surendra S Katyare
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lea MadiPnina Fishman
Apr 7, 2007·Alternatives to Laboratory Animals : ATLA·Petr MlejnekPetr Dolezel
Sep 21, 2007·Journal of Cellular Biochemistry·Ivo Frydrych, Petr Mlejnek
Nov 22, 2007·Pharmacology & Therapeutics·Stefania GessiPier Andrea Borea
Feb 15, 2008·BMC Cancer·Ruoping TangJean-Pierre Marie
Citations
Jan 13, 2011·Annals of Hematology·Petr MlejnekPetr Kosztyu
Nov 28, 2012·Journal of Physiology and Biochemistry·Petr MlejnekIvo Frydrych
Dec 14, 2011·Acta Physiologica·P B Persson
Aug 7, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hamideh AbediSima Hajiahmadi
Apr 5, 2011·Expert Opinion on Investigational Drugs·Balázs KoscsóGyörgy Haskó
Jul 20, 2010·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Petr DolezelPetr Mlejnek
Aug 25, 2015·Experimental Eye Research·Joana GalvaoAna Raquel Santiago
Jul 13, 2011·The Biochemical Journal·Wen-Hsin Liu, Long-Sen Chang
Apr 27, 2011·Journal of Cellular Physiology·Petr MlejnekPetr Kosztyu
Jun 19, 2019·Journal of Cellular Biochemistry·Petr MlejnekEliska Ruzickova
Oct 18, 2014·European Journal of Haematology·Petr KosztyuPetr Mlejnek
Jun 24, 2014·Chemico-biological Interactions·Petr KosztyuPetr Mlejnek
Jul 8, 2014·Chemico-biological Interactions·Petr Mlejnek, Petr Dolezel